key: cord-0853847-wzfox00o authors: Attallah, Nizar; Gupta, Sudeendra; Madhyastha, Rakesh; El Nekidy, Wasim S.; Mallat, Jihad title: Anticoagulation in COVID-19 patients requiring continuous renal replacement therapy date: 2021-03-19 journal: Anaesth Crit Care Pain Med DOI: 10.1016/j.accpm.2021.100841 sha: 2da6764dc1956faa6228a0028c56a717de4f3abb doc_id: 853847 cord_uid: wzfox00o nan Dear Editor, Ever since December 2019, the number of patients with SARS-CoV-2 infection continues to increase [1] . The incidence of acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT) in critically ill patients with severe SARS-CoV-2 infection is significant [2] . The requirement of continuous renal replacement therapy (CRRT) varies according to various risk factors such as admission to the intensive care unit (ICU), the requirement of vasopressors, and mechanical ventilation. Patients with stage-3 AKI usually need support with CRRT [2] . Various studies have shown that patients with SARS-CoV-2 infection are at an increased risk of systemic thrombosis due to hypercoagulable state, as suggested by the elevated D-dimer, Von Willebrand Factor antigen activity, and factor VIII activity [3] . One theory proposed that the complete lack of clot lysis might contribute to thromboembolic events in this population, especially if accompanied with acute kidney failure [4] . Hypercoagulability could enhance clotting of the CRRT filter and compromise the CRRT efficiency [5] . Hence, anticoagulation is essential to maintain the patency of the extracorporeal circuit [5] . Data describing clotting and anticoagulation in patients with SARS-CoV-2 requiring CRRT are scarce… We sought to describe our experience where we needed to use higher doses than usual of anticoagulation therapy in this population. This is a retrospective analysis of the CRRT filter clotting and the newly implemented anticoagulation protocols in patients with confirmed SARS-CoV-2 infection admitted to the ICU and received CRRT at our quaternary care hospital. Data collection was commenced after we received the Research Ethics Committee approval. All consecutive adults admitted to the ICU during the 3 study periods were enrolled. Cliquez ici pour afficher les références liées filter clotting, and also post filter aPTT. The post filter aPTT was checked on daily basis through the peripheral venous blood and the target aPTT range was 40-60 seconds. The pre filter replacement percentage is typically 50-100%. Regional citrate was rarely used. The number of patients with COVID-19 infection admitted to the ICU started increasing in our hospital since late March 2020. We noticed a significant reduction in optimal CRRT filter's half-life secondary to frequent clotting. At the same time, published reports showed a higher incidence of clotting in this population [3, 4] . We compared the CRRT filter's life over 3 periods of time to investigate the efficiency of the new protocol. The first period was from the 1 st of January 2020 until the 29 th of February 2020; prior to the pandemic, during which, we were using the standard protocol (described earlier) and we did not have any proven COVID-19 patients in the ICU. 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 Table 1 describes the patients' demographics and filter life in the 3 periods. Kruskal-Wallis test was used to assess statistical significance between medians. The median filter life of period 1 was significantly higher than that of period 2 (p = 0.02), which was in turn significantly lower than the median filter life of period 3 (p = 0.01) ( Table 1 ). The mean duration of CRRT per 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 J o u r n a l P r e -p r o o f patient was 7 + 2 days during period 1, 11 + 1 days during period 2, and 9 + 2 days during period 3. As described earlier, with the adjustment of heparin and using the systemic IV heparin protocol significantly improved the filter life. However, we did not look at other thromboembolic events outside the dialysis filter. In the meantime, there was no major bleeding in those who received the new IV heparin protocol. Patients with severe SARS-CoV-2 infections can develop multiorgan failure and the coagulation profile could resemble the disseminated intravascular coagulopathy but usually presents with thrombosis and not bleeding [3, 4] . Using aPTT to monitor anticoagulation with unfractionated heparin in any inflammatory state may not reflect the underlying anticoagulant activity. It may be skewed by the increased levels of factor VIII and fibrinogen and low levels of antithrombin. Using anti-Xa activity may reflect better picture of the coagulation state in this population. That was not done given the retrospective nature of the study [4] . In conclusion, higher dosing of circuit and/or intravenous heparin lowers the incidence of clotting and prolongs filter life during CRRT in patients with severe SARS-CoV-2 infections, which may improve patients' outcomes. Anti-Xa activity could better be used to monitor the anticoagulation state in this population rather than aPTT . 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 J o u r n a l P r e -p r o o f 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 Acute kidney injury in patients hospitalized with COVID-19 High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection The datasets generated and/or analysed during the current study are not publicly available due to privacy (patients' data) but are available from the corresponding author on reasonable request. All 5 authors participated in the study design and reviewing of the patients' information and results. All 5 authors are responsible for the integrity of the data. NA, SG, and RM collected data. Data analysis was performed by NA, JM and WSE. NA, SG, and RM wrote the first draft of the manuscript. All authors contributed scientifically to the subsequent versions. All authors read and approved the final manuscript. The authors declare that they have no competing interests.